NCT03715023

Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients

A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Pulmocide Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study tests the effects of an experimental drug PC786 in people infected with Respiratory Syncytial Virus (RSV). PC786 may be useful in treating patients infected with RSV as it works by interfering with the way the virus multiplies. PC786 is an inhaled medicine. Participants will be treated with SoC treatment (e.g. oral ribavirin and/or IV immunoglobulin), half of the participants will receive PC786 in addition and half will receive a placebo treatment. The study will take place at multiple sites in UK and will include approximately 30 participants. The maximum study duration will be about 4 weeks.

Conditions

• Respiratory Syncytial Virus Infections

Interventions

Type	Name	Description
DRUG	PC786	PC786 suspension for inhalation
DRUG	Placebo	Placebo solution for inhalation
DRUG	SOC	Standard treatment for RSV infection at study site

Timeline

• Start date: 2018-11-05
• Primary completion: 2019-02-19
• Completion: 2019-05-01
• First posted: 2018-10-22
• Last updated: 2019-06-12

Locations

7 sites across 1 country: United Kingdom